1621 related articles for article (PubMed ID: 26596670)
21. [Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma].
Yan S; Jin S; Wang PF; Yan LZ; Shang JJ; Shi XL; Wu XJ; Zhai YY; Yao WQ; Wang J; Yao Y; Fu CC
Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):819-825. PubMed ID: 37394852
[No Abstract] [Full Text] [Related]
22. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Bradbury CA; Craig Z; Cook G; Pawlyn C; Cairns DA; Hockaday A; Paterson A; Jenner MW; Jones JR; Drayson MT; Owen RG; Kaiser MF; Gregory WM; Davies FE; Child JA; Morgan GJ; Jackson GH
Blood; 2020 Aug; 136(9):1091-1104. PubMed ID: 32438407
[TBL] [Abstract][Full Text] [Related]
23. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.
Touzeau C; Perrot A; Hulin C; Manier S; Macro M; Chretien ML; Karlin L; Escoffre M; Jacquet C; Tiab M; Leleu X; Avet-Loiseau H; Jobert A; Planche L; Corre J; Moreau P
Blood; 2024 May; 143(20):2029-2036. PubMed ID: 38394666
[TBL] [Abstract][Full Text] [Related]
24. Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real-world single-centre experience.
Sim S; Quach H; Pham T; Smooker V; Filshie R
Intern Med J; 2024 Jan; 54(1):108-114. PubMed ID: 37357752
[TBL] [Abstract][Full Text] [Related]
25. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
Segeren CM; Sonneveld P; van der Holt B; Vellenga E; Croockewit AJ; Verhoef GE; Cornelissen JJ; Schaafsma MR; van Oers MH; Wijermans PW; Fibbe WE; Wittebol S; Schouten HC; van Marwijk Kooy M; Biesma DH; Baars JW; Slater R; Steijaert MM; Buijt I; Lokhorst HM;
Blood; 2003 Mar; 101(6):2144-51. PubMed ID: 12456509
[TBL] [Abstract][Full Text] [Related]
26. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
Mauz-Körholz C; Landman-Parker J; Balwierz W; Ammann RA; Anderson RA; Attarbaschi A; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Claviez A; Daw S; Dieckmann K; Fernández-Teijeiro A; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kluge R; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH
Lancet Oncol; 2022 Jan; 23(1):125-137. PubMed ID: 34895479
[TBL] [Abstract][Full Text] [Related]
27. Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma.
Ria R; Falzetti F; Ballanti S; Minelli O; Di Ianni M; Cimminiello M; Vacca A; Dammacco F; Martelli MF; Tabilio A
Hematol J; 2004; 5(2):118-22. PubMed ID: 15048061
[TBL] [Abstract][Full Text] [Related]
28. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
Tap WD; Papai Z; Van Tine BA; Attia S; Ganjoo KN; Jones RL; Schuetze S; Reed D; Chawla SP; Riedel RF; Krarup-Hansen A; Toulmonde M; Ray-Coquard I; Hohenberger P; Grignani G; Cranmer LD; Okuno S; Agulnik M; Read W; Ryan CW; Alcindor T; Del Muro XFG; Budd GT; Tawbi H; Pearce T; Kroll S; Reinke DK; Schöffski P
Lancet Oncol; 2017 Aug; 18(8):1089-1103. PubMed ID: 28651927
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
Dimopoulos MA; Delforge M; Hájek R; Kropff M; Petrucci MT; Lewis P; Nixon A; Zhang J; Mei J; Palumbo A
Haematologica; 2013 May; 98(5):784-8. PubMed ID: 23242595
[TBL] [Abstract][Full Text] [Related]
30. [Updated treatment strategy for transplant-eligible multiple myeloma: current status and future perspectives].
Tsukada N
Rinsho Ketsueki; 2023; 64(9):1066-1073. PubMed ID: 37899184
[TBL] [Abstract][Full Text] [Related]
31. Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients.
Spencer A; Seldon M; Deveridge S; Cobcroft R; Cull G; Marlton P; Enno A; Gill D
Hematol J; 2004; 5(3):216-21. PubMed ID: 15167907
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K
Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771
[TBL] [Abstract][Full Text] [Related]
33. Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries.
Abildgaard N; Anttila P; Waage A; Rubin KH; Ørstavik S; Bent-Ennakhil N; Gavini F; Ma Y; Freilich J; Hansson M
Eur J Cancer; 2024 Apr; 201():113921. PubMed ID: 38377776
[TBL] [Abstract][Full Text] [Related]
34. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
Robinson GW; Rudneva VA; Buchhalter I; Billups CA; Waszak SM; Smith KS; Bowers DC; Bendel A; Fisher PG; Partap S; Crawford JR; Hassall T; Indelicato DJ; Boop F; Klimo P; Sabin ND; Patay Z; Merchant TE; Stewart CF; Orr BA; Korbel JO; Jones DTW; Sharma T; Lichter P; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Sanders RP; Onar-Thomas A; Ellison DW; Gajjar A; Northcott PA
Lancet Oncol; 2018 Jun; 19(6):768-784. PubMed ID: 29778738
[TBL] [Abstract][Full Text] [Related]
35. A comparison of allografting with autografting for newly diagnosed myeloma.
Bruno B; Rotta M; Patriarca F; Mordini N; Allione B; Carnevale-Schianca F; Giaccone L; Sorasio R; Omedè P; Baldi I; Bringhen S; Massaia M; Aglietta M; Levis A; Gallamini A; Fanin R; Palumbo A; Storb R; Ciccone G; Boccadoro M
N Engl J Med; 2007 Mar; 356(11):1110-20. PubMed ID: 17360989
[TBL] [Abstract][Full Text] [Related]
36. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
Guman T; Sykora J
Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839
[TBL] [Abstract][Full Text] [Related]
37. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
Morgan GJ; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Cook G; Feyler S; Johnson PR; Rudin C; Drayson MT; Owen RG; Ross FM; Russell NH; Jackson GH; Child JA;
Haematologica; 2012 Mar; 97(3):442-50. PubMed ID: 22058209
[TBL] [Abstract][Full Text] [Related]
38. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Dunavin NC; Wei L; Elder P; Phillips GS; Benson DM; Hofmeister CC; Penza S; Greenfield C; Rose KS; Rieser G; Merritt L; Ketcham J; Heerema N; Byrd JC; Devine SM; Efebera YA
Leuk Lymphoma; 2013 Aug; 54(8):1658-64. PubMed ID: 23194056
[TBL] [Abstract][Full Text] [Related]
39. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.
Chang H; Samiee S; Yi QL
Leuk Lymphoma; 2006 Jan; 47(1):43-7. PubMed ID: 16321826
[TBL] [Abstract][Full Text] [Related]
40. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
Schjesvold FH; Ludwig H; Mateos MV; Larocca A; Abdulhaq H; Norin S; Thuresson M; Bakker NA; Richardson PG; Sonneveld P
Eur J Haematol; 2024 Mar; 112(3):402-411. PubMed ID: 37968873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
